COVID-19 Laboratory Resource Center
Updated 3/27/20 4:28 PM PDT
COVID-19 Test Billing Updates
With information changing frequently, XIFIN is in daily discussions with each of the major payors, to confirm billing code assignment, any billing specific requirements, and reimbursement information. We will continue to provide live updates as we receive them.
Due to the emergent nature of the public health concern surrounding the novel coronavirus testing, both the Centers for Medicare and Medicaid Services (CMS) and the American Medical Association (AMA) developed specific billing codes to help increase testing and track new cases.
On February 13, 2020, CMS developed a new Healthcare Common Procedure Coding System (HCPCS) code for providers and laboratories to test patients for SARS-CoV-2. HCPCS code U0001 is used for CDC testing laboratories. On February 29, 2020, the Food and Drug Administration (FDA) issued a new policy for certain laboratories to develop their own validated COVID-19 diagnostic test. HCPCS code U0002 was announced on March 5, 2020, which allows these laboratories to bill for non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).
On March 13, 2020, the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel convened in a special meeting and approved a new code to describe the laboratory test for severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2). Although, not included in the 2020 CPT publication, CPT code 87635 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique; is effective immediately for use to report this test service. It will be included in the 2021 code set in the Microbiology subsection under the Pathology and Laboratory section of the CPT manual.
COVID-19 Billing Resources and Updates
COVID-19: Steps XIFIN Is Taking
With the Coronavirus Disease 2019 (COVID-19) continuing its spread around the world, we at XIFIN recognize the responsibility we have to our employees, customers, and partners during this critical time. The health and well-being of our team, our clients, and our clients’ employees are of the utmost importance to us.
As a critical partner to your business, we understand that limiting the impact of this health event on our service is imperative. We are keenly focused on our business continuity planning efforts to maintain a safe work environment for our associates and to sustain our business operations.
Security and safety are integral to our products, business processes, and infrastructure. We have a robust, global, integrated Business Continuity Program in place that is managed by a dedicated team of experts who are working hard to keep our operations running smoothly so that we can provide you with the best possible service.
As such, we have activated our Business Continuity Plan, which includes:
We will continue to monitor this fluid situation and will shift workloads as necessary to do what we can to ensure essential services remain fully operative. XIFIN has demonstrated support to our clients in past emergency situations, and in dealing with the present circumstances, we remain unwavering in our efforts to deliver essential services to all our clients. We are keeping those directly affected by this virus in our thoughts, and send our best wishes for health and safety.